We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 354

Avalon Ventures closes ninth and largest fund

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 13 2011

Avalon Ventures, located near San Diego, California, has reportedly closed capital commitments of $200 million for its ninth and largest fund, Avalon Ventures IX, LP

Comments sought on guidelines for nanotoxicology research papers

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 20 2012

Nature Nanotechnology editors have initiated an effort to develop guidelines that would apply to researchers submitting papers on the toxicity of various nanomaterials

PROLOR Biotech to raise $75 million for clinical trials on growth hormones

  • Shook Hardy & Bacon LLP
  • -
  • Israel, USA
  • -
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million

Moneytree report shows increased life sciences investments in Q1 2011

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall

Pharmacy and hospital interests present comments on proposed compounding bill

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 20 2013

Proposed legislation (S. 959) that would give the U.S. Food and Drug Administration (FDA) the authority to oversee compounding pharmacies that ship

Research institution creates regional biomedical hub in Florida

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

The Jackson Laboratory, a Maine-based biomedical research institution, has announced a partnership to develop "genetics-based" treatments for heart disease, Alzheimer's disease and diabetes at a new 120,000-square-foot research facility in Sarasota County, Florida

Federal court denies HHS motion to seal documents in medical-device whistleblower

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • January 10 2013

A federal court in the District of Columbia has denied the government's request to seal an exhibit in Freedom of Information Act litigation over records

U.S. biotech clusters face challenges and opportunities

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 24 2011

Genetic Engineering & Biotechnology News has published a two-part perspective on the top U.S. biotechnology hubs, exploring how they have weathered the recession and their goals for expansion

New biotech initiative in San Francisco

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • December 16 2010

San Francisco has reportedly started a new initiative to expand biotech and life-sciences startups in areas that include Mission Bay, Pier 70 and the former Hunters Point Naval Shipyard

Senate approves bill to crack down on counterfeit drugs

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 15 2012

The U.S. Senate has unanimously passed a bill (S. 1886) that would increase penalties for trafficking counterfeit drugs “to reflect the severity of the crime and the harm to the public.”